Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy

NCT04861779 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT04861779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04861779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 24, 2021
Completion date
October 31, 2023
Enrollment
156 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell malignancies